| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
52,040,000 |
| Market
Cap: |
75.98(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.47 - $3.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Unity Biotechnology is a biotechnology company engaged in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Co. focuses on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases. Co.'s ophthalmology program includes UBX1325, which is its main drug candidate for age-related diseases of the eye including diabetic macular edema, age-related macular degeneration and diabetic retinopathy. Co.'s neurology program includes UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
603 |
2,466 |
8,726 |
73,618 |
| Total Sell Value |
$935 |
$4,121 |
$21,645 |
$86,858 |
| Total People Sold |
1 |
1 |
1 |
2 |
| Total Sell Transactions |
1 |
3 |
9 |
23 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tompkins Tamara |
See Remarks |
• – – |
2020-06-22 |
4 |
D |
$9.67 |
$24,011 |
D/D |
(2,483) |
42,847 |
|
- |
|
| Marquess Dan |
Chief Scientific Officer |
• – – |
2020-06-22 |
4 |
D |
$9.67 |
$24,011 |
D/D |
(2,483) |
380,690 |
|
- |
|
| Leonard Keith R |
Director |
– • – |
2020-06-22 |
4 |
D |
$9.67 |
$45,555 |
D/D |
(4,711) |
89,546 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2020-06-22 |
4 |
D |
$9.67 |
$24,011 |
D/D |
(2,483) |
161,027 |
|
- |
|
| David Nathaniel E |
President |
• • – |
2020-06-22 |
4 |
D |
$9.67 |
$24,011 |
D/D |
(2,483) |
2,324,703 |
|
- |
|
| Dananberg Jamie |
Chief Medical Officer |
• – – |
2020-06-22 |
4 |
D |
$9.67 |
$24,011 |
D/D |
(2,483) |
452,219 |
|
- |
|
| David Nathaniel E |
President |
• • – |
2020-06-05 |
4 |
B |
$8.90 |
$28,478 |
D/D |
3,200 |
2,327,186 |
2.81 |
-49% |
|
| David Nathaniel E |
President |
• • – |
2020-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
24,255 |
2,323,986 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2020-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
29,106 |
163,510 |
|
- |
|
| Tompkins Tamara |
See Remarks |
• – – |
2020-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
24,255 |
45,330 |
|
- |
|
| Marquess Dan |
Chief Scientific Officer |
• – – |
2020-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
24,255 |
381,297 |
|
- |
|
| Dananberg Jamie |
Chief Medical Officer |
• – – |
2020-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
24,255 |
454,702 |
|
- |
|
| Ghosh Anirvan |
Chief Executive Officer |
• • – |
2020-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2020-02-24 |
4 |
OE |
$3.43 |
$34,300 |
D/D |
10,000 |
134,404 |
|
- |
|
| Dananberg Jamie |
Chief Medical Officer |
• – – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
21,075 |
430,447 |
|
- |
|
| Leonard Keith R |
Chief Executive Officer |
• • – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
210,782 |
|
- |
|
| Marquess Dan |
Chief Scientific Officer |
• – – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
21,075 |
357,041 |
|
- |
|
| David Nathaniel E |
President |
• • – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
21,075 |
2,299,731 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
21,075 |
124,404 |
|
- |
|
| Tompkins Tamara |
See Remarks |
• – – |
2019-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
21,075 |
21,075 |
|
- |
|
| Leonard Keith R |
Chief Executive Officer |
• • – |
2019-06-19 |
4 |
OE |
$3.40 |
$68,000 |
D/D |
20,000 |
170,782 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2018-10-10 |
4 |
OE |
$3.43 |
$17,150 |
D/D |
5,000 |
101,348 |
|
- |
|
| Berns Paul L |
Director |
– • – |
2018-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
3,261 |
3,261 |
|
- |
|
| Goeltz Ii Robert C. |
Chief Financial Officer |
• – – |
2018-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,630 |
96,348 |
|
- |
|
| Leonard Keith R |
Chief Executive Officer |
• • – |
2018-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,630 |
150,782 |
|
- |
|
81 Records found
|
|
Page 3 of 4 |
|
|
0.04 (2.82%) 
